Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bonetti

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Journal for Immunotherapy of Cancer|May 9, 2025
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Karim Rihawi, Francesca Mazzoni, et al.
Journal of Translational Medicine|November 30, 2013
The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22Massimo Pancione, Andrea Remo, Caterina Zanella, et al.
British Journal of Cancer|January 13, 2017
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancerFederica Marmorino, Lisa Salvatore, Cecilia Barbara, et al.
Future Oncology (London, England)|January 24, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationaleElisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, et al.
Recenti Progressi in Medicina|June 15, 2021
The process of EUSOMA certification improves the quality of breast cancer care: the experience of an Italian EUSOMA certificated Breast Unit (BU) according to the results of a cross-sectional studyDiana Gazzani, Alberto Dai Prè, Roberto Sandrini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trialCarlo Aschele, Luca Cionini, Sara Lonardi, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
Systematic and Applied Microbiology|October 6, 2019
Characterization of Bifidobacterium species in feaces of the Egyptian fruit bat: Description of B. vespertilionis sp. nov. and B. rousetti sp. novMonica Modesto, Maria Satti, Koichi Watanabe, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Journal for Immunotherapy of Cancer|May 9, 2025
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Karim Rihawi, Francesca Mazzoni, et al.
Journal of Translational Medicine|November 30, 2013
The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22Massimo Pancione, Andrea Remo, Caterina Zanella, et al.
British Journal of Cancer|January 13, 2017
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancerFederica Marmorino, Lisa Salvatore, Cecilia Barbara, et al.
Future Oncology (London, England)|January 24, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationaleElisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, et al.
Recenti Progressi in Medicina|June 15, 2021
The process of EUSOMA certification improves the quality of breast cancer care: the experience of an Italian EUSOMA certificated Breast Unit (BU) according to the results of a cross-sectional studyDiana Gazzani, Alberto Dai Prè, Roberto Sandrini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trialCarlo Aschele, Luca Cionini, Sara Lonardi, et al.
The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
Systematic and Applied Microbiology|October 6, 2019
Characterization of Bifidobacterium species in feaces of the Egyptian fruit bat: Description of B. vespertilionis sp. nov. and B. rousetti sp. novMonica Modesto, Maria Satti, Koichi Watanabe, et al.
Pageof 14